The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.
A large U.K. trial found that routine use of cerebral embolic protection did not decrease the incidence of stroke within 72 hours among patients undergoing TAVI.
New research links high levels of micronanoplastics in carotid artery plaque to stroke symptoms, suggesting a potential new target for cardiovascular disease prevention.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
"Greater cumulative CVH and improvement in CVH during young adulthood, as well as better CVH in middle age, were all independently associated with lower risk for incident CVD in midlife."